{"schema_version":"secwatch.filing_event.v1","accession":"0001689375-26-000052","form_type":"8-K","ticker":"TRDA","cik":"0001689375","company_name":"Entrada Therapeutics, Inc.","filed_at":"2026-08-05T11:04:39+00:00","discovered_at":"2026-08-05T11:05:00.318095+00:00","generated_at":"2026-08-05T11:05:48.187547+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Entrada reports Q2 net loss of $42.8M; cash $223M; multiple clinical data readouts ahead","bullets":["Net loss of $42.8M in Q2 2026, roughly flat vs $43.1M in Q2 2025; collaboration revenue $0.9M.","Cash, equivalents and marketable securities $223.0M as of June 30, 2026, down from $295.7M at Dec 31, 2025; runway into Q3 2027.","ELEVATE-44-201 Cohort 1 open-label data expected by year-end 2026; Cohort 2 data in Q1 2027.","ELEVATE-45-201 Cohort 1 data expected October 2026; Cohort 2 dosing at 10 mg/kg ongoing with data in H1 2027.","Vertex to report VX-670 Phase 1/2 data in DM1 in H2 2026; Entrada advancing preclinical ocular candidate ENTR-801 for USH2A."],"urls":{"canonical":"https://secwatch.observer/filing/0001689375-26-000052","json":"https://secwatch.observer/filing/0001689375-26-000052.json","markdown":"https://secwatch.observer/filing/0001689375-26-000052.md","text":"https://secwatch.observer/filing/0001689375-26-000052.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689375/000168937526000052/0001689375-26-000052-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689375/000168937526000052/trda-20260805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T11:05:48.187547+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}